REGN

From a fundamental perspective, Regeneron's valuation metrics appear attractive. The Price-to-Earnings (P/E) ratio is 14.9, with a forward P/E of 13.6, suggesting that the stock is trading at a discount relative to its earnings growth potential. However, the company's earnings per share (EPS) growth has declined by 7.2% quarter-over-quarter, which raises concerns about future profitability. Despite this, revenue has grown by 19.0% quarter-over-quarter, indicating robust demand for its products. Analysts maintain a consensus "BUY" rating, with 5 strong buy and 16 buy recommendations, and a target price of $833.31, representing a potential upside of approximately 36%. This optimistic outlook is supported by the recent positive developments regarding the new drug application for cemdisiran, which has received attention from both the FDA and EMA.

Regeneron does not have an earnings report scheduled within the next 30 days, but the most recent data from the last quarter on March 31, 2026, is crucial for context. The acceptance of cemdisiran's new drug application is a significant catalyst that could enhance future revenue streams, particularly if it leads to successful market entry. Investors should closely monitor the company's progress with this drug, as it could substantially impact revenue growth and overall market sentiment. As the market awaits further developments, the focus will be on how Regeneron manages its growth trajectory amidst the backdrop of fluctuating earnings and competitive pressures in the biotechnology sector.